Evidence map›Paper›PMID 40229302›Full record

ArticleScientific reports2025

Integrated renin angiotensin system dysregulation and immune profiles predict COVID-19 disease severity in a South African cohort.

Talitha Müller, Sonwabile Dzanibe, Cascia Day, Phelelani Thokozani Mpangase, Tafadzwa Chimbetete, Sarah Pedretti, Sylva Schwager, Clive M Gray, Edward Sturrock, Jonny Peter

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Talitha MüllerDivision of Allergology and Clinical Immunology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Sonwabile DzanibeDivision of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Cascia DayDivision of Allergology and Clinical Immunology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Phelelani Thokozani MpangaseSydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Tafadzwa ChimbeteteDivision of Allergology and Clinical Immunology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Sarah PedrettiAllergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.
Sylva SchwagerDepartment of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Clive M GrayDivision of Molecular Biology and Human Genetics, Stellenbosch University, Stellenbosch, South Africa.
Edward SturrockDepartment of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Jonny PeterDivision of Allergology and Clinical Immunology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. Jonny.Peter@uct.ac.za.

Funding

IMmune-mediated Adverse drug Reactions In African HIV endemic setting (IMARI-SA study)K43TW011178 · FIC · UNIVERSITY OF CAPE TOWN LUNG INSTITUTE · PI PETER, JONATHAN · 2018 to 2022
$648k
FIC NIH HHS K43 TW011178South African Medical Research Council GIPD Project Code:96825South African Medical Research Council GIPD Project Code:96830Wellcome Trust
6 · The paper itself

Abstract

Renin-angiotensin system (RAS) dysregulation is an important component of the complex pathophysiology of SARS-CoV-2 and other coronavirus infections. Thus, angiotensin-converting enzyme 2 (ACE2), the entry receptor and key to the alternative RAS, was proposed as a severity/prognostic biomarker for risk-stratification. However, experimental RAS data from diverse cohorts are limited, particularly analyses integrating RAS with immune biomarkers. Participants (n = 172) in Cape Town were sampled longitudinally (including a recovery timepoint [> 3-month]), across WHO asymptomatic to critical severity. Using fluorometric assays and LC-MS/MS RAS Fingerprinting

Indexed as

COVID-19Renin-Angiotensin SystemAdultAgedAngiotensin-Converting Enzyme 2BiomarkersCohort StudiesFemaleHumansMaleMiddle AgedPeptidyl-Dipeptidase APrognosisSARS-CoV-2Severity of Illness IndexSouth AfricaACE2 protein, humanAngiotensin-Converting Enzyme 2BiomarkersPeptidyl-Dipeptidase AACE2BiomarkersCOVID-19MDSCRASSARS-CoV-2

Identifiers

PMID40229302
PMCPMC11997227

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.